Evaluation of effectiveness of Kutajashtaka in the treatment of Asrigdara (Abnormal Uterine Bleeding)

A Clinical Study to Evaluate the Efficacy of Kutajashtaka in the Management of Asrigdara - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067329

Enrollment

Registered

2024-05-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing for trial Patients having any of the following symptoms Excessive bleeding Per Vagina amount more than 80ml Prolonged bleeding Per Vagina With the duration of bleeding more than 7 days Patients of age group 17 to 45 years Hb equal to or greater than 8gm per dl

Exclusion criteria

Exclusion criteria: Pregnant woman Patients having bleeding due to abortion Ectopic Pregnancy Any type of malignancy Patients using IUCDs Thyroid hormones abnormalities Uterine and pelvic pathology like Polyps Endometrial T.B Fibroid Adenomyosis PID

Design outcomes

Primary

Measure	Time frame
To evaluate the therapeutic efficacy and safety of Kutajashtaka in the management of AsrigdaraTimepoint: 1 month	—

Secondary

Measure	Time frame
To study the ayurvedic and modern concept about asrigdaraTimepoint: 1 month	—

Countries

India

Contacts

Public ContactDr Prabha Kumari

Government Ayurvedic College and Hospital Patna Bihar

dr.prabhapandey@yahoo.in7004860634

Outcome results